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Abstract
Background: Activating Transcription Factor (ATF) 3 is a key regulator of the cellular integrated stress response
whose expression has also been correlated with pro-apoptotic activities in tumour cell models. Combination
treatments with chemotherapeutic drugs, such as cisplatin, and histone deacetylase (HDAC) inhibitors have been
demonstrated to enhance tumour cell cytotoxicity. We recently demonstrated a role for ATF3 in regulating
cisplatin-induced apoptosis and others have shown that HDAC inhibition can also induce cellular stress. In this
study, we evaluated the role of ATF3 in regulating the co-operative cytotoxicity of cisplatin in combination with an
HDAC inhibitor.
Results: The HDAC inhibitor M344 induced ATF3 expression at the protein and mRNA level in a panel of human
derived cancer cell lines as determined by Western blot and quantitative RT-PCR analyses. Combination treatment
with M344 and cisplatin lead to increased induction of ATF3 compared with cisplatin alone. Utilizing the MTT cell
viability assay, M344 treatments also enhanced the cytotoxic effects of cisplatin in these cancer cell lines. The
mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways and dependent on
ATF4, a known regulator of ATF3 expression. ATF4 heterozygote (+/-) and knock out (-/-) mouse embryonic
fibroblast (MEF) as well as chromatin immunoprecipitation (ChIP) assays were utilized in determining the
mechanistic induction of ATF3 by M344. We also demonstrated that ATF3 regulates the enhanced cytotoxicity of
M344 in combination with cisplatin as evidenced by attenuation of cytotoxicity in shRNAs targeting ATF3
expressing cells.
Conclusion: This study identifies the pro-apoptotic factor, ATF3 as a novel target of M344, as well as a mediator of
the co-operative effects of cisplatin and M344 induced tumour cell cytotoxicity.
Background
Alteration of gene expression plays an a role in tumouri-
genesis and progression of cancer. Modulation of gene
expression, for example, tumour suppressors or onco-
genes, are not exclusively due to mutations and can be
manipulated through transcriptional regulation mechan-
isms which include DNA methylation and histone modifi-
cation [1]. In cancer cells, the balance between histone
acetylation and deacetylation catalyzed by histone
acetyltransferases and histone deacetylases (HDAC),
respectively, is often disrupted. For example, altered
expression and aberrant recruitment of HDACs have been
reported in tumours [2]. HDACs catalyze the removal of
acetyl groups from histones resulting in chromatin con-
densation and transcriptional repression [1,3,4]. HDAC
inhibitors act to reverse this transcriptional silencing of
genes, which include tumour suppressors [1,3,4]. HDAC
inhibitors are generally small molecule inhibitors that can
readily diffuse across cellular membranes and directly
interact with the zinc ion at the base of the catalytic
pocket of this enzyme blocking substrate interaction and
activity [1]. Coupled with their ability to induce cell cycle
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inhibitors have been evaluated as cancer therapeutic
agents [1,3,4]. Currently the HDAC inhibitor, vorinostat,
has been FDA approved for clinical use for treatment
against cutaneous T-cell lymphoma [5].
cis-Diamminedichloroplatinum(II) (cisplatin) is among
the most active anti-tumour agent used in human che-
motherapy and widely used in various tumour types
including lung and ovarian cancers [6]. Acquired resis-
tance and toxicities associated with treatment are major
impediments inhibiting their efficacy [7]. Cisplatin is pri-
marily considered as a DNA-damaging agent that forms
various types of bi-functional adducts in reaction with
cellular DNA [6]. Cisplatin becomes activated intra-cellu-
larly by the aquation of one of two chloride leaving
groups, and subsequently covalently binding to DNA,
forming DNA adducts [8]. The final cellular outcome of
DNA adduct formation is generally apoptotic cell death,
thought to occur through halting of cellular processes
such as replication and transcription leading to pro-
longed G2 phase cell-cycle arrest, and deregulation of
signal transduction pathways involved in growth, differ-
entiation, and stress responses [7]. Cellular mechanisms
of resistance to platinum-based chemotherapeutics are
multifactorial and contribute to severe limitation in their
use in clinical practice. They include molecular events
inhibiting drug-DNA interaction, such as a reduction in
cisplatin accumulation inside cancer cells or inactivation
by thiol-containing species [6]. Other mechanisms of
resistance acting downstream to the initial reaction of
cisplatin with DNA, include an increase in adduct repair
and a decrease in induction of apoptosis [7].
Pre-clinical and clinical studies have demonstrated
that HDAC inhibitors can enhance the anticancer activ-
ity of a variety of epigenetic as well as chemotherapeutic
agents including cisplatin [2,9]. For example, promising
clinical trials combining platins as well as other che-
motherapeutics with HDAC inhibitors have been con-
ducted [10,11]. The ability of HDAC inhibitors to
enhance the anti-cancer activity of known chemothera-
peutic drugs is believed to be related to their function
as positive regulators of gene transcription. As such,
HDAC inhibitors have pleiotropic effects and can alter
the expression of a wide variety (1000 s) of genes [1-3].
In particular, HDAC inhibitor treatment has been
shown to augment expression of genes such as cell cycle
suppressor, p21, apoptotic factors related to both extrin-
sic (death receptors and ligands) and intrinsic (Bcl-2
family members) pathways, and angiogenic factors such
as HIF1a and VEGF [1-3].
It is well established that HDAC inhibitors can enhance
the anticancer activity of cisplatin in vitro in a variety of
cancer cell models [12-17]. Few studies exist, however,
detailing the mechanism of enhanced anti-cancer effects
by HDAC inhibitors in combination with cisplatin. For
example, Rikiishi et al, correlated enhanced cytotoxicity
by HDAC inhibitors in combination with cisplatin with
reduced levels of the antioxidant intracellular reduced
glutathione (GSH) in an oral squamous cell carcinoma
model [18]. Our recent work has demonstrated that
cisplatin treatment induces Activation of Transcription
Factor (ATF) 3, a member of the ATF/cyclic AMP
response element-binding family, regulates cisplatin-
induced cytotoxicity [19]. ATF3 expression is induced by
a wide variety of stress causing agents including hypoxia,
metabolic stress and DNA damage [20]. ATF3 is also
induced in times of physiological stress such as liver
regeneration [21], brain seizure [22], ischemia-reperfu-
sion of the heart and kidney [23], and nerve damage [24].
ATF3 has been shown to play a role in apoptosis and
proliferation, two cellular processes critical for cancer
progression [25-28]. Divergence in function of ATF3
between a pro-and anti-apoptotic factor in cancer models
is dependent on both cellular model and state of malig-
n a n c y[ 8 , 2 5 , 2 8 ] .A c t i v a t i o no fA T F 3b yaw i d ea r r a yo f
stress signalling pathways have been demonstrated
including DNA repair pathway components p53 [29,30],
the integrated stress response (ISR) that is principally
activated by hypoxia and metabolic stress [31], and the
MAPKinase cascades (SAPK/JNK, p38 and ERK) [32,33].
I nt h i ss t u d yw ei d e n t i f yan o v e lt a r g e to ft h eH D A C
inhibitor M344, showing that treatment induced up-
regulation of the stress inducible transcription factor
ATF3. We show that M344 treatment can induce
ATF3 expression at the protein and mRNA level in a
panel of human derived cell lines. We also show that
combination treatment with cisplatin and M344 could
enhance induction of ATF3 compared with cisplatin
alone. Likewise, M344 treatment increased the cyto-
toxic effects of cisplatin on the human cancer cell
lines. Unlike cisplatin whose mechanistic induction of
ATF3 was shown previously to be dependent on the
MAPKinase pathways [19], ATF3 induction by M344
was found to be independent of the MAPKinase path-
ways and reliant on the ISR pathway. Finally, we corre-
lated increased ATF3 expression with the enhanced
cytotoxicity of M344 in combination with cisplatin
utilizing ATF3 shRNA expressing cell lines. Taken
together, this study identifies the pro-apoptotic factor,
ATF3 as a novel target of HDAC inhibitors, as well as
a novel factor regulating the co-operative effects of
cisplatin and HDAC inhibitor induced cytotoxicity.
Material and Methods
Tissue Culture
The A549, PC3, and MCF-7 cell lines were obtained
from American Type Culture Collection (ATCC; Rock-
ville, MD). The SK-OV3 cell line was kindly provided by
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Institute (OHRI), Ottawa, Canada. The MEFs used in
this study were derived from heterozygote (+/-) and
knockout mice (-/-) from an ATF4 murine model
(kindly provided by D. Park, University of Ottawa,
Ottawa, Ontario). All cell lines were maintained in
DMEM supplemented with 10% fetal bovine serum
(FBS; Medicorp, Montreal, Canada) and 100 units peni-
cillin and 100 μg streptomycin (GIBCO, Burlington,
ON)/ml of media. ATF4 (-/-) MEFs were maintained in
DMEM containing 10% fetal bovine serum, 0.1 mM
nonessential amino acids, 55 μM 2-mercaptoethanol,
and 100 units penicillin and 100 μg streptomycin/ml of
media. Cells were exposed to the HDAC inhibitor,
4-(Dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-
benzamide (M344) (Sigma, St.L o u i s ,M I ) ,o rc i s p l a t i n
(provided by the pharmacy at the Ottawa Hospital
Regional Cancer Centre, Ottawa) alone or in combina-
tion with the p38 inhibitor SB203580 (Calbiochem,
Gibbstown, NJ), JNK inhibitor, JNK inhibitor II
(SP600125) (Calbiochem) or ERK inhibitor UO126
(Calbiochem) diluted in DMSO.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) Assay
In a 96-well flat-bottomed plate (Nunc, Naperville, IL)
~5,000 cells/150 μL of cell suspension were used to seed
each well. The cells were incubated overnight to allow
for cell attachment and recovery. Cells were treated with
indicated drugs and incubated for 48 hrs at 37°C. Follow-
ing treatment, 42 μL of a 5 mg/mL solution in PBS of the
MTT tetrazolium substrate (Sigma) was added to each
well and incubated for ~ 20 min at 37°C. The resulting
violet formazan precipitate was solubilised by the addi-
tion of 82 μL of a 0.01 mol/L HCl/10% SDS (Sigma) solu-
tion, and allowed to further incubate at 37°C overnight.
The plates were then analyzed on an MRX Microplate
Reader from Dynex Technologies (West Sussex, UK) at
570 nm to determine the absorbance of the samples.
Design and expression of small hairpin RNAs
The two 19 mer sequences targeting ATF3 mRNA are; #1-
5′-GCCAAAGAATATTCCATTT-3′ and #2- 5′-GGG
AGGGCCTGCAGTGATT-3′ to pSuper vector from Oli-
goengine small hairpin RNA (shRNA) (#1: nucleotides
1524-1542; GenBank accession number NM_001030287.
#2: nucleotides 1270-1289; GenBank accession number
NM_001030287) target sequence. As controls, we used
the GFP-targeted oligonucleotide 5′CATGCGTCCAC
TCTTCCTC-3′ with accession number NC_011521.
These sequences were BLAST confirmed for specificity.
The forward and reverse synthetic 60 nt oligonucleotides
(Integrated DNA Technologies, Coralville, IA) were
designed, annealed, and inserted into the BglII/HindIII
sites of pSUPER.retro.puro vector, following the manufac-
turer’s instructions (Oligoengine, Seattle, WA). These con-
structs express a 19 mer targeting two independent
location within ATF3 mRNA or GFP (control shRNA)
mRNAs. The retroviral packaging cell line, RetroPack
PT67 (Clonetech Laboratories, Mountain View, CA) was
used for stable virus production according to the manufac-
turer’s instructions. Briefly, packaging cells were trans-
fected with ATF3-shRNA plasmids#1, #2 or GFP-shRNA,
using FuGENE® HD Transfection Reagent (Roche, Missis-
sauga, ON). After generation of stable clones and determi-
nation of viral titre, A549 cells were infected with viral
supernatant using 4 μg/ml polybrene. Stable transfected
clones expressing shRNAs were selected using 3 μg/ml
puromycin.
Western Blot Analysis
Cells plated at 0.7 ×10
6 per 60 mm dish were allowed to
grow overnight and treated with indicated drug for 24
hrs. Protein samples were collected in RIPA buffer (50
mM Tris-CL pH 7.5, 150 mM sodium chloride, 1 mM
EDTA, 1% Triton-X-100, 0.25% sodium deoxycholate,
0.1% SDS) containing 50 mM sodium fluoride, 1 mM
sodium orthovanadate, 10 mM b-glycerolphosphate and
1× Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis,
MO). Protein concentrations were assayed using Bio-
Rad Protein Assay (Mississauga, Ontario, Canada) and a
Biomate 3 Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). Protein extracts representing 40 μg
were separated on a 10% SDS-PAGE gel and electro-
phoretically transferred to a polyvinylidene difluoride
membrane (Immobilon-P, Millipore, Billerica, MA).
Membranes were blocked in 5% skim milk powder in
Tris-buffered saline containing 10% Tween-20 (TBS-T)
for 1 hr at room temperature followed by incubation
with primary antibody diluted in 5% skim milk in TBS-
T with shaking overnight at 4°C. Polyclonal antibody
ATF3 was purchased from Santa Cruz, Santa Cruz, CA.
Monoclonal anti-actin was purchased from Sigma-
Aldrich, St. Louis, MO. Polyclonal antibody to PARP
was purchased from Cell Signalling Technology, Beverly,
MA. Polyclonal antibodies against HSP27 and phospho-
HSP27 (Ser78) were purchased from Stessgen, Ann
Arbor, MI. Following washes in TBS-T, blots were incu-
bated with the appropriate HRP-labelled secondary anti-
body for 1 hr at room temperature. Visualization of
protein bands was performed using the Supersignal
West Pico Chemiluminescent Substrate (Pierce, Rock-
ford, IL) exposed on Kodak film in a Konica Minolta
SRX-101A tabletop processor.
RT-RNA isolation and RT-PCR
MCF-7 cells plated at 0.8 ×10
6 cells per 10 cm dish
were incubated at 37°C overnight. The next day cells
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combination for 24 hrs. Total RNA was extracted using
the RNeasy1 kit (Qiagen, Mississauga, ON). RNA con-
centrations were quantified using a NanoDrop ND-1000
spectrophotometer (NanoDrop, Wilmington, DE). One
microgram of total RNA was reverse-transcribed to
complementary DNA for quantitative, real-time, reverse-
transcriptase polymerase chain reaction (RT-PCR) as
previously described [34]. The Applied Biosystems AB
7500 Real-Time PCR system (Applied Biosystems, Foster
City, CA) was used to detect amplification. Real-time
PCR reactions were carried out in a total volume of 25
μlt h a tc o n t a i n e d2 . 5μl of synthesized cDNA (42 ng),
1.25 μl of TaqMan Gene Expression Assay Primer/
Probe (20× (Applied Biosystems, ATF3, HS00231069),
12.5 μl of TaqMan Universal PCR Master Mix (2×
(Applied Biosystems, 4304437) and 8.75 μlo fR N a s e -
free water for ATF3 expression. The endogenous control
for ATF3 was the housekeeping gene, human GAPDH
(20× (Applied Biosystems, HS4333764-F). Amplification
conditions were 95°C for 5 min, 40 PCR cycles at 95°C
for 15 sec and 60°C for 1 min. Three independent
experiments were performed to determine the average
gene expression and standard deviation.
Chromatin Immunoprecipitation (ChIP) Assay
Cells treated for 24 hrs in 10 cm dishes were fixed with
1% formaldehyde (BDH, VWR International, Missis-
sauga, ON) for 20 min at room temperature in order to
cross-link the DNA and protein. The cross-linking was
quenched by adding glycine to a final concentration of
200 mM and incubating at room temperature for
5 min. Cells were then washed twice with ice-cold PBS
and harvested in 1 mL cold PBS by centrifugation at
4°C for 5 min at 5,000 rpm. The pellet was resuspended
in 90 μL lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM
EDTA pH 8.0, 1% SDS) supplemented with 1× Protease
Inhibitor Cocktail (Sigma-Aldrich), 1 mM 1,4-dithio-
DL-threitol (DTT) (Sigma-Aldrich), and 1 mM phenyl-
methylsulfonyl fluoride (PMSF) (Sigma-Aldrich). The
lysates were sonicated using a Sonicator 3000 (Misonix,
Farmingdale, NY) at power setting #1 for a total of
3 min on ice with 10 sec on/off pulses to shear the
DNA to an average size of 300 to 1000 base pairs. Soni-
cated lysates were cleared of debris by centrifugation for
15 min at 14, 000rpm at 4°C. Input controls were
removed from each sample and stored at -20°C. Soni-
cated lysates were divided into negative controls and
samples, then diluted 10-fold with dilution buffer (20
mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA pH
8.0, 1% Triton X-100) supplemented with 1× Protease
Inhibitor Cocktail (Sigma-Aldrich), 1 mM DTT (Sigma-
Aldrich), and 1 mM PMSF (Sigma-Aldrich). Positive
sample cell lysates were immunoprecipitated by
overnight rotation at 4°C with rabbit anti-acetyl H4
(1:200, Millipore) primary antibody. Negative controls
were incubated overnight with rotation at 4°C in the
absence of primary antibody.
Immune complexes were collected by 2 hr rotation at
4°C with the addition of 40 μL of protein A agarose/sal-
mon sperm DNA 50% slurry (Millipore) to both samples
and negative controls. The agarose beads/immune com-
plexes were then pelleted gently by centrifugation for
1 min at 3, 000 rpm at 4°C. The beads were washed
w i t h1m Lo ft h ef o l l o w i n gb u f f e r sb yr o t a t i o nf o r
10 min at 4°C, then pelleted gently by centrifugation for
1 min at 3,000 rpm at 4°C, discarding the supernatant
following each wash: Buffer A (low salt; 0.1% SDS, 1%
Triton X-100, 20 mM Tris-HCl pH 8.0, 2 mM EDTA
pH 8.0, 150 mM NaCl) once, Buffer B (high salt; 0.1%
SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.0, 2 mM
EDTA pH 8.0, 500 mM NaCl) once, Buffer C (1% NP-
40, 1% sodium deoxycholate, 20 mM Tris-HCl pH 8.0,
1 mM EDTA pH 8.0, 0.25 M LiCl) once, TE washing
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0)
twice. Freshly prepared elution buffer (1% SDS, 100 mM
NaCHO3) was added to all samples (input and negative
controls, and samples) to a final volume of 400 μLa n d
samples were rotated at room temperature for 30 min.
The agarose beads were removed from the samples by
centrifugation for 1 min at 3,000 rpm.
The DNA-protein cross-linking was reversed by over-
night incubation with 5 μL proteinase K (20 mg/mL,
Roche Diagnostics, Laval, QC, CAN) at 65°C. The DNA
was purified using a QiaQuick PCR Purification Kit (Qia-
gen) according to the manufacturer’s instructions. Puri-
fied DNA was eluted in 50 μLd d H 2Oa n ds a m p l e sw e r e
stored at -80°C. Conventional PCR was performed with
amplification conditions as follows; 95°C for 2 min, 40
PCR cycles of 95°C for 30 sec, 58°C for 30 sec, 72°C for
30 sec, and finally 72°C for 5 min. The binding of acetyl
H4 to the ATF3 and p21 proximal promoter regions
were determined using the following primer pairs: ATF3,
forward-5′ CCGAACTTGCATCACCA GTGC, reverse-
5′ GAGCTGTGCAGTGCGCGCC; p21, forward-
GGTGTC TAGGTGCTCCAGGT, reverse
-GCACTCTCCAGGAGGACACA [35]. PCR products
were resolved on 1.6% agarose gels.
Results
HDAC inhibition induces ATF3 expression and enhances
cisplatin cytotoxicity
We have recently demonstrated that ATF3 expression
plays a role in cisplatin induced cytotoxicity [19]. Given
the emerging role of HDAC inhibitors as anti-cancer
agents, we evaluated whether ATF3 also regulates their
activities. Indeed we found that M344 treatment, a
potent pan HDAC inhibitor, could affect ATF3
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(5 μM) dose of M344 in a panel of human derived can-
cer cell lines, MCF-7 (breast adenocarcinoma), PC3
(prostate carcinoma), SK-OV3 (ovarian carcinoma), and
A549 (lung carcinoma) demonstrated consistent up-
regulation of ATF3 protein expression (Figure 1A).
Since our previous work had shown that cisplatin could
also induce ATF3 expression, we evaluated ATF3
expression following combinational treatment with
M344 and cisplatin. M344 treatment (1 and 5 μM) in
combination with cisplatin (10 μg/ml) for 24 hrs
enhanced induction of ATF3 compared with cisplatin
treatment alone as determined by Western blot analysis
(Figure 1B). M344 inductiono fA T F 3e x p r e s s i o nw a s
also evaluated at the mRNA level in the MCF-7 cell line
and found to be similarly induced under these experi-
mental conditions (Figure 1C). Differences in ATF3
mRNA expression, although not statistically significant
likely due to high variability of transcript induction
between experiments, was generally additive in combi-
nation treatments compared with M344 and cisplatin
treatment alone (Figure 1C). Since it has been shown
that HDAC inhibitors can enhance the cytotoxicity of
cisplatin, we confirmed this previous observation in the
MCF-7 and SK-OV3 cell lines where combination treat-
ment lead to approximately 20% increased cytotoxicity
compared with cisplatin treatment alone (Figure 2A) as
measured by the MTT cell viability assay. The observed
enhanced cytotoxicity was also demonstrated by cell
imaging following either cisplatin, M344 alone, or in
combinational treatment in the MCF-7 cell line for
48 hrs (Figure 2B). A low dose of cisplatin was used
(2 μg/ml) which does not induce significant cytotoxicity
in the MCF-7 cell line (Figure 2A, top panel) however,
following combination treatment with M344 (5 μM)
enhanced cytotoxicity was clearly evident in the corre-
sponding phase contrast images (Figure 2B). In sum-
mary, these data demonstrate that M344 is a novel
inducer of ATF3 and an enhancer of ATF3 induction
when in combination with cisplatin treatment. Increased
ATF3 expression mediated by combinational treatment
correlates with increased cytotoxicity compared with
cisplatin alone.
ATF3 induction by M344 is regulated by the Integrated
Stress Response
Next, we evaluated a number of cell signalling pathways
that are known regulators of ATF3 expression to deter-
mine the mechanism of induction of ATF3 by M344.
Our previous work had identified the MAPKinase path-
ways as mediators of ATF3 induction by cisplatin. Simi-
larly, other groups had shown the involvement of
MAPKinase pathways in mediating ATF3 induction
through other stress inducing agents [32]. We evaluated
Figure 1 M344 induces ATF3 and enhances its expression in
combination with cisplatin treatment. A, ATF3 protein expression
levels following 24 hr treatment with control, DMSO vehicle, and,
low and high doses of M344 (1 and 5 μM) in MCF-7, PC3, SK-OV3
and A549 cell lines. B, ATF3 protein expression levels following
24 hrs treatment with cisplatin (10 μg/ml), or cisplatin in
combination with M344 (1 and 5 μM) in MCF-7 and SKOV-3 cell
lines. In all blots actin is used as a loading control. C, ATF3 mRNA
quantified by quantitative RT-PCR of MCF-7 cells comparing
untreated treated control, DMSO vehicle, M344 (1 and 5 μM),
cisplatin (10 μg/ml), or cisplatin in combination with M344 (5 μM)
for 24 hrs. Error bars are representative of quantified mRNA from
three independent experiments normalized to GAPDH expression.
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to the JNK (SP600125), and ERK (UO126) as well as
p38 (SB203580) pathways in all the cell lines used in
this study. Unlike our previous data which showed that
all inhibitors to these pathways could down regulate the
induction of ATF3 by cisplatin consistently in all the
same cell lines (MCF-7, PC3, SKOV-3 and A549), these
inhibitors did not affect ATF3 induction by M344
treatment. This data essentially eliminates the MAPKi-
nase pathways as regulators of ATF3 induction by M344
(Figure 3A). Although, decreased expression of ATF3
was observed following M344 treatment in the presence
of JNK inhibitor in the MCF-7 cell line and ERK inhibi-
tor in the SKOV-3 cell line, lack of consistency between
cell lines allows us to conclude that MAPKinase path-
ways are likely not involved in mediating ATF3 induc-
tion by M344. In contrast, the ERK pathway inhibitor,
UO126, could increase ATF3 expression when treated
in combination with M344 on the A549 and PC3 cell
lines (Figure 3A). Since ATF3 is a known stress induci-
ble gene, the combination of M344 and inhibition of the
ERK pathway, whose function is to mediate cell growth
and differentiation, may specifically induce higher levels
of ATF3 as a stress responsive cellular event. Of note in
these cell lines, the inhibitors tested consistently inhib-
ited ATF3 induction by cisplatin indicating a role for
these MAPKinase cascades in cisplatin [19] but not
M344 induction of ATF3 expression.
To rule out the involvement of the p38 MAPKinase
pathway which we had previously shown had the most
significant role in ATF3 induction by cisplatin, we more
rigorously analyzed the role of the p38 MAPKinase
pathway in M344 induction of ATF3. To determine the
involvement of the pathway in mediating M344 induc-
tion of ATF3 the p38 specific inhibitor, SB203580 (SB),
was utilized at increasing doses in the presence of M344
treatment for 24 hrs in the MCF-7 cell line. The path-
way was effectively down regulated following inhibitor
treatment in a dose dependent manner as measured by
the phosphorylation status of heat shock protein 27
(HSP27), a downstream effector of the p38 pathway,
however ATF3 expression was unaffected (Figure 3B).
Controls included no treatment, DMSO was used as a
control for the M344 vehicle, and TNFa as a positive
control for p38 activation. To confirm this observation
we also determined the mRNA expression of ATF3 fol-
lowing M344 treatment in the absence and presence of
the p38 pathway inhibitor in the MCF-7 cell line and
found no significant difference in ATF3 expression
between treatments (Figure 3C). Taken together, these
data confirm a MAPKinase independent mechanism as
a mediator of ATF3 induction by M344.
Previously our laboratory had identified lovastatin, a
potent inhibitor of mevalonate synthesis, as an inducer
of the ISR pathway and subsequent mediator of lovasta-
tin-induced apoptosis [34]. Downstream effectors of the
ISR pathway include members of the ATF family of
transcription factors, ATF4 and its downstream target
ATF3 [31]. Therefore, we looked at the potential invol-
vement of the ISR pathway, and specifically ATF4, as a
mediator of ATF3 induction by M344. We tested the
ability of M344 to induce ATF3 expression in
Figure 2 M344 enhances the cytotoxicity of cisplatin.A ,M C F - 7
and SK-OV3 cell lines treated with cisplatin (0-10 μg/ml) in the
presence (grey) or absence (black) of M344 (1 μM) for 48 hrs was
assessed for cell viability employing the MTT assay. Data is
represented as a percentage of MTT activity where untreated cells
were taken to be 100%. Error bars are representative of six replicates
of two independent experiments. B, Phase contrast images of MCF-
7 cells treated with no treatment (control), cisplatin (2 μg/ml), M344
(1 μM) and cisplatin and M344 in combination for 48 hrs.
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MEFs, the upstream inducer of ATF3 expression in the
ISR pathway. Using thapsigargin, a well established
inducer of the ISR, as a positive control [36], we show
in Figure 4A that the absence of ATF4 completely inhi-
bits ATF3 induction by M344 revealing an ISR depen-
dent mechanism.
Since it has been shown that HDAC inhibition can
mediate induction of genes by directly influencing the
acetylation of histones surrounding the gene thus pro-
moting transcription, we performed a ChIP assay to
evaluate the association between acetylated Histone 4
(AcH4) and the ATF3 promoter. Chromatin was iso-
lated from the MCF-7, and PC3 cell lines following
treatment with solvent control or M344 at 1 and 5 μM
doses. Chromatin- protein complexes were pulled down
with an antibody against AcH4 and the DNA was
assessed for the presence of the ATF3 promoter region.
In both cell lines, pull down with AcH4 antibody in the
untreated cells yielded the presence of the ATF3 promo-
ter without significant enhancement with M344 treat-
ment (Figure 4B). Following M344 treatment, ATF3
gene expression was increased as compared with control
cells (see Figure 1), however, ATF3 promoter expression
associated with AcH4 was not increased as compared
Figure 3 ATF3 induction by M344 is independent of MAPKinase
pathways. A, A549, MCF-7, PC3 and SKOV-3 cells untreated (control),
and treated with DMSO, or M344 (5 μM) for 24 hrs in the absence
(control) or presence of MAPKinase pathway inhibitors SP600125
(50 μM), UO126 (25 μM), and SB203580 (10 μM) and analyzed by
Western blotting for ATF3 and actin. B, MCF-7 cells untreated
(control), treated with DMSO, TNFa for 15 min, or with M344 (5 μM)
in the absence or presence of p38 inhibitor, SB203580 (5 and 10 μM)
for 24 hrs were analyzed for ATF3, actin, phospho-HSP27 (p-hsp27),
and total HSP27 expression by Western blotting. C. ATF3 mRNA
quantified by quantitative RT-PCR of MCF-7 cells untreated (control),
treated with M344 (5 μM) or M344 in the presence of SB203580
(10 μM) for 24 hrs. Error bars are representative of quantified mRNA
from three independent experiments.
Figure 4 M344 induced ATF3 is mediated through the
Integrated Stress Response. A, Western blot analysis for ATF3 and
actin in ATF4 (+/-) and (-/-) MEFs treated with solvent control,
thapsigargin (1 μM), M344 (1 and 5 μM) for 24 hrs. B, Chromatin
Immunoprecipication (ChIP) assay of chromatin/DNA complexes
isolated from MCF-7 cells treated with solvent control or M344 (5
μM) for 24 hrs using acetylated Histone 4 (AcH4) antibody and
analyzing by PCR for presence of ATF3 or p21 promoter regions.
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ATF3 by M344 is independent of histone acetylation
association with the ATF3 gene promoter. As a control,
M344 treatment induced AcH4 at the p21 promoter, a
well established target of HDAC inhibition whose
expression is up-regulated through promoter histone
acetylation [35]. These data suggest the induction of
ATF3 by M344 to be indirect and related to its activa-
tion and induction of effectors of the ISR.
ATF3 regulates, in part, the enhanced cytotoxicity of
cisplatin and M344
To determine whether ATF3 expression affects the
enhanced cytotoxicity observed between cisplatin and
HDAC inhibitor treatments, we evaluated ATF3 induc-
tion by M344 and cisplatin combination treatment in
the A549 cell line. As demonstrated for the MCF-7 and
S K - O V 3c e l l si nF i g u r e2 A ,t h ec o m b i n e dd r u gt r e a t -
ments in A549 cells was associated with increased cyto-
toxicity compared to cisplatin treatment alone as
analyzed by the MTT cell viability assay (Figure 5A).
Furthermore, the combined treatment of cisplatin and
M344 also resulted in enhanced ATF3 expression as
compared with cisplatin and M344 alone as observed by
Western blotting (Figure 5B). Likewise, PARP cleavage,
a marker of apoptosis, was observed to increase follow-
ing cisplatin and M344 treatment in combination com-
pared with M344 and cisplatin treatment alone (Figure
5B). To further elucidate the role of ATF3 in enhanced
cytotoxicity by HDAC inhibitors in combination with
cisplatin, we expressed shRNA targeting ATF3 in the
A549 cell line. To determine the role of ATF3 expres-
sion in drug-mediated cytotoxicity, GFP (negative con-
trol), shATF3 1 and 2 stably expressing cell lines that
target two distinct sequences of the ATF3 gene were
treated with cisplatin alone (Figure 6A) or cisplatin in
combination with M344 (Figure 6B) and analyzed by the
MTT assay. As previously reported [19], the shRNA
expressing ATF3 targeted A549 cell lines showed atte-
nuated cisplatin induced cytotoxicity as compared with
GFP control (Figure 6A). M344 (1 μM) treatment in
combination with cisplatin enhanced cell cytotoxicity as
compared with cisplatin alone in all cell lines (Figure 6A
and 6B). Cytotoxicity was also attenuated in both of the
shATF3 cell lines compared with GFP control when
treated with cisplatin in combination with M344 (Figure
6B). Cisplatin (2 μg/ml) and M344 (1 μM) combined
treatment enhanced ATF3 expression in the GFP con-
trol while ATF3 induced expression was reduced in the
shRNA targeting ATF3 A549 cells with these treatments
(Figure 6C). Since the inhibition of ATF3 expression
inhibits the enhanced cytotoxicity of this drug combina-
tion, these data provide evidence that ATF3 plays a role
in mediating the enhanced cytotoxic response.
Discussion
In this study, we identified ATF3 as a novel consistently
inducible target of HDAC inhibitor treatment in a panel
of human derived cancer cell lines both at the protein
and mRNA level. Similarly in a very recent study, ATF3
was identified as one of a number of genes induced fol-
lowing a genetic screen of an HDAC inhibitor in sensi-
tive colon cancer cell lines although the mechanism of
induction was not characterized [37]. This is the first
study to characterize this regulation in multiple cancer
c e l ll i n e sa sw e l la sa d d r e s st h em e c h a n i s mo fH D A C
inhibition induced ATF3 expression. Regulators of
ATF3 expression include the MAPKinase pathways as
well as ISR activation. In M344 treatments, MAPKinase
pathways, including the p38, ERK and JNK pathways,
Figure 5 ATF3 mediates, in part, the enhanced cytotoxicity between M344 and cisplatin. A, A549 cells treated with cisplatin alone (0-10
μg/ml), or with M344 (1 μM) for 48 hrs were assessed for cell viability as measured by MTT activity. Data is represented as a percentage of MTT
activity where untreated cells were taken to be 100%. Error bars are representative of six replicates of two independent experiments. B, A549
cells treated with solvent control, M344 alone (1 and 5 μM), cisplatin (2 μg/ml) alone or in combination with M344 (1 and 5 μM) were analyzed
by Western blotting for ATF3, PARP and actin.
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by this HDAC inhibitor. In contrast, we have recently
demonstrated that these same MAPKinase pathways
regulate cisplatin induced ATF3 expression. To address
the role of MAPKinases, we employed specific inhibitors
to these pathways in a cancer cell line panel and found
no consistent inhibition of M344 mediated ATF3 induc-
tion. Interestingly, we observed an up regulation of
ATF3 expression when treating A549 and PC3 cell lines
with M344 in combination with the ERK inhibitor
UO126. Combination treatment of the MEK/ERK inhi-
bitor UO126 and the HDAC inhibitor SAHA lead to
increased apoptosis in leukemia cell lines [38], however,
ATF3 levels were not assessed [38].
In this study, we provide evidence for the involvement of
the ISR pathway as mediator of M344 induction of ATF3.
M344 induced expression of ATF3 was completely abol-
ished in ATF4 (-/-) MEFs implicating an ISR dependent
mechanism downstream of ATF4. In accordance with this
finding, the endoplasmic reticulum chaperone protein
glucose-regulated protein 78 (GRP78) was recently identi-
fied as a non-histone target of SAHA, whose action leads
to dissociation of GRP78 and its client protein, double-
stranded RNA-activated protein-like ER kinase (PERK),
and subsequent activation of the ISR through the induc-
tion of the endoplasmic reticulum stress response includ-
ing activation of ATF4 [39]. Since ATF3 is a known
effector of the ISR pathway downstream of ATF4 [36], our
finding that M344 induces ATF3 may be mediated by
HDAC inhibitor mediated acetylation of GRP78. Further-
more, we also demonstrated through ChIP assay of the
ATF3 promoter that levels of acetylated histone H4/chro-
matin were independent of M344 suggesting the induction
of ATF3 was not the result of increased histone acetylation
at the ATF3 promoter.
A role for ATF3 in tumourigenesis has been impli-
cated through its documented role as an apoptotic
factor in cancer models, whose mechanism may be
related to ATF3′s role in transcriptional regulation of a
number of regulators of apoptosis and cell proliferation
including pro-apoptotic factor, GADD153/CHOP and
cell cycle factor, cyclin D1, respectively [40,41]. Depend-
ing on the cell type and the type and severity of the cell
stressor, ATF3 has been implicated as both a proto-
oncogene and tumour suppressor. Examples of ATF3 as
a pro-apoptotic include an ATF3 over-expression model
which lead to inhibition of proliferation and induced
cell cycle arrest in human cancer cells [27], and loss of
ATF3 in a Ras transformed model which resulted in
higher proliferation rates and increased G1 to S phase
transition efficiency [28].
As stated, HDACs catalyze the removal of acetyl
groups from histones resulting in chromatin condensa-
tion and transcriptional repression [1,2]. HDAC inhibi-
tors reverse this transcriptional silencing of genes,
including tumour suppressors [1,2]. Coupled with their
ability to induce such anti-cancer cellular processes as
cell cycle arrest, apoptosis, and disruption of angiogen-
esis, HDAC inhibitors have been studied for their poten-
tial as cancer therapeutic agents [1-4]. Cisplatin, on the
other hand, is considered a DNA-damaging anticancer
drug forming different types of bi-functional adducts in
reaction with cellular DNA. The final cellular outcome
of DNA adduct formation is generally apoptotic cell
death, thought to occur through halting of cellular pro-
cesses such as replication and transcription leading to
prolonged G2 phase cell-cycle arrest and deregulation of
signal transduction pathways involved in growth, differ-
entiation, and stress responses [7]. There is a growing
body of evidence that demonstrates that HDAC inhibi-
tors can enhance the anticancer activity of a variety of
chemotherapeutic drugs, including cisplatin [12-17,42].
Previous reports have attempted to identify the factors
related to HDAC inhibitors ability to enhance cisplatin
Figure 6 Targeting ATF3 expression inhibits M344 and cisplatin co-operative cytotoxicity. A, A549 cells stably expressing GFP or shATF3-1
and shATF3-2 were treated with cisplatin (1-5 μg/ml) for 48 hrs and analysed for MTT activity as above. B, A549 cells stably expressing GFP or
shATF3-1 and shATF3-2 were treated with cisplatin in the presence of M344 (1 μM) for 48 hrs and analysed for MTT activity as above. * Statistical
analysis, Paired T-test P < 0.005 between GFP and both shATF3 sub-lines. C, A549 cells stably expressing GFP (negative control), or short hairpin
RNA against two separate ATF3 mRNA regions (shATF3-1) and (shATF3-2) were untreated, treated with cisplatin (10 μg/ml) or cisplatin in
combination with M344 (5 μM) for 24 hrs and analyzed by Western blotting for ATF3 and actin expression.
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antioxidant intracellular reduced glutathione or the
involvement of the endoplasmic reticulum stress
response as a mediator of the enhancement of cytotoxi-
city in the same cancer model [43]. Up-regulation of the
expression by HDAC inhibitors in apoptosis associated
proteins p53, BID, cytochrome c and caspase-3 have
also been proposed as targets of HDAC inhibitors that
can enhance cisplatin-induced cytotoxicity [16]. In this
study we identified the transcription factor ATF3 as a
mediator of enhanced cisplatin induced cytoxicity by
HDAC inhibition. Identification of the specific pathway
(s) of apoptotic cell death related to ATF3′sr o l ea s
mediator of enhanced cytotoxicity by combinational
treatment merits further investigation.
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